Zydus Life Science
Zydus Lifesciences Ltd
- Market Cap
- ₹1,19,700 Cr
- P/E
- 28.63
Key Fundamentals
LargecapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 21.10%
- Debt to Equity
- 0.50
- EPS (TTM)
- ₹41.92
- Book Value
- ₹278.88
- Market Cap
- ₹1,19,700 Cr
- P/E (TTM)
- 28.63
- P/B
- 4.30
- ROE
- 21.20%
- Dividend Yield
- 0.08%
- EBITDA
- ₹8,985 Cr
- 52W High
- ₹1,266.60
- 52W Low
- ₹835.50
- Day Range
- ₹1,193.50 – ₹1,208.50
- Volume
- 7,80,371
Peer Comparison
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
| 1,884.90 | 41.25 | 4,52,251 | 5.07 | 0.85% | 16.00% | 20.50% | 61,631 | 10,987 | |
| 11,180.50 | 88.26 | 2,96,807 | 16.49 | 0.27% | 16.50% | 22.00% | 12,191 | 3,363 | |
| 4,689.50 | 77.80 | 1,78,374 | 9.71 | 0.82% | 27.40% | 15.20% | 17,400 | 2,099 | |
| 2,294.60 | 92.52 | 1,23,980 | 20.45 | 0.04% | 18.30% | 17.80% | 7,823 | 1,332 | |
| 1,200.00 | 28.63 | 1,19,700 | 4.30 | 0.08% | 21.20% | 21.10% | 30,378 | 4,303 | |
| 1,390.20 | 41.44 | 1,16,037 | 2.99 | 0.57% | 11.20% | 13.00% | 33,097 | 2,760 | |
| 1,415.00 | 39.45 | 1,14,312 | 3.23 | 0.92% | 11.60% | 15.50% | 28,139 | 2,855 | |
| Median 7 companies | 1,884.90 | 41.44 | 1,23,980 | 5.07 | 0.57% | 16.50% | 17.80% | 28,139 | 2,855 |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 36
- Poor
- Returns, margins, earnings quality 22% weight
- Valuation
- 61
- Good
- Cheap vs sector & own history 24% weight
- Growth
- 73
- Strong
- Sales & profit trajectory 9% weight
- Financial Health
- 31
- Poor
- Solvency, leverage, coverage 9% weight
- Momentum
- 39
- Weak
- Trend strength, vol-adjusted 12% weight
- Ownership
- 50
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Company has delivered good profit growth of 18.8% CAGR over last 5 years
No weaknesses listed
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 3 | 6 | 10 |
| Oscillators | Bullish | 1 | 6 | 2 |
| Moving Averages | Strong Bullish | 2 | 0 | 8 |
Oscillators
Bullish
Overall
Strong Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 54.44
- Neutral
- MACD (12,26,9)
- 10.94
- Bearish
- SMA (50)
- 1,166.18
- Bullish
- SMA (200)
- 1,056.53
- Bullish
As of
Analyst Rating
15 of 29 analysts rate Buy, 8 Hold, 6 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 10Y | +11.16% |
|---|---|
| 5Y | +13.51% |
| 3Y | +16.35% |
| 1Y | +16.81% |
| TTM | +24.02% |
Net profit
| 10Y | +10.06% |
|---|---|
| 5Y | +18.59% |
| 3Y | +34.80% |
| 1Y | +9.65% |
| TTM | −14.45% |
Operating cash flow
| 10Y | +1.12% |
|---|---|
| 5Y | −8.46% |
| 3Y | −7.66% |
| 1Y | −68.78% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +6.48 pp |
|---|---|
| 5Y | +7.68 pp |
| 3Y | +8.83 pp |
| 1Y | +0.85 pp |
| TTM | −4.13 pp |
Revenue by year
| Mar 2017 | ₹9,376 Cr |
|---|---|
| Mar 2018 | ₹11,905 Cr |
| Mar 2019 | ₹13,166 Cr |
| Mar 2020 | ₹14,253 Cr |
| Mar 2021 | ₹14,404 Cr |
| Mar 2022 | ₹15,110 Cr |
| Mar 2023 | ₹17,237 Cr |
| Mar 2024 | ₹19,547 Cr |
| Mar 2025 | ₹23,242 Cr |
| Mar 2026 | ₹27,148 Cr |
Net profit by year
| Mar 2017 | ₹1,517 Cr |
|---|---|
| Mar 2018 | ₹1,810 Cr |
| Mar 2019 | ₹1,899 Cr |
| Mar 2020 | ₹1,204 Cr |
| Mar 2021 | ₹2,185 Cr |
| Mar 2022 | ₹4,618 Cr |
| Mar 2023 | ₹2,092 Cr |
| Mar 2024 | ₹3,973 Cr |
| Mar 2025 | ₹4,673 Cr |
| Mar 2026 | ₹5,124 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Zydus Lifesciences trades at ₹1,204.2 as of 2026-11-17 with a market cap of ₹1,20,119 crore and a P/E of 28.73x. The company has delivered strong compounded sales growth of 14% over five years and profit CAGR of 18.8% over the same period, though TTM profit growth has turned negative at -10% even as TTM revenue growth accelerated to 24%.
- Strong long-term profit growth with 18.8% CAGR over the last five years, well above the broader pharma sector average
- TTM revenue growth of 24% indicates robust top-line momentum and potential market share gains
- Consistent return on equity averaging 21% over the last three and five years, reflecting efficient capital deployment
- ROCE of 19.24% signals healthy returns on total capital employed, supporting reinvestment capacity
- Manageable leverage with a debt-to-equity ratio of just 0.42, providing financial flexibility for future expansion or acquisitions
- Stock has delivered a 1-year CAGR of 30% and a 5-year CAGR of 21%, demonstrating sustained investor confidence
- Compounded sales growth of 16% over three years and 14% over five years shows a durable revenue trajectory across cycles
- Trading roughly 5% below its 52-week high of ₹1,266.6, indicating the stock has held near peak levels rather than correcting sharply
- TTM profit growth has turned negative at -10% despite 24% revenue growth, suggesting margin compression or one-off cost pressures
- P/E of 28.73x is elevated for a company whose most recent profit trend is declining, raising questions about valuation sustainability
- Dividend yield of just 0.08% offers negligible income return, making the stock almost entirely dependent on capital appreciation
- The divergence between 24% TTM sales growth and -10% TTM profit growth points to deteriorating operating leverage or rising input costs
- 10-year compounded profit growth of 11% is materially lower than the recent 3-year figure of 32%, suggesting recent gains may not be structurally sustainable
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Zydus is executing an aggressive diversification strategy with Rs 136 billion invested in capex and acquisitions over FY24-26, highlighted by the Sterling Biotech API acquisition and Sunshine Healthcare JV. The standout positive is saroglitazar's strong Phase 2b MASH data, which opens a large therapeutic opportunity. The key risk is the 5 FDA observations at the Moraiya facility (45% of US sales), which requires swift remediation to avoid escalation to a Warning Letter. The trend is net positive given pipeline momentum and analyst upgrades, but regulatory remediation progress will be a near-term overhang to watch.
- US FDA flags Moraiya facility Oct 26
US FDA issued 5 observations after Oct 5-13 inspection citing data integrity gaps, inadequate investigation of a metal shaving in a tablet (Class II recall), and batches released exceeding assay control limits. Moraiya accounts for ~45% of US sales.
- LIC reduces stake significantly Nov 6
LIC cut its holding in Zydus Lifesciences to 3.184% after selling 20,242,068 shares in the open market between August 2025 and November 2026.
- Saroglitazar MASH Phase 2b success Nov 6
Saroglitazar 4mg achieved 39.1% steatohepatitis resolution vs 13.7% placebo (P=0.002) in a 189-patient Phase 2b trial over 52 weeks, with no significant weight gain or liver injury signal. Results support advancement to larger studies.
- Sterling Biotech API deal closed Nov 2
Zydus completed acquisition of Sterling Biotech's API business on November 2, 2026, after fulfillment of all conditions precedent.
- Sunshine Healthcare JV finalized Nov 12
Zydus subscribed to 50% equity in ZyduS Sunshine joint venture with Sunshine Healthcare Lanka on November 11, 2026.
- New auditor Walker Chandiok appointed Nov 4
Walker Chandiok & Co LLP appointed as statutory auditors for a 5-year term starting FY27, replacing Deloitte under mandatory rotation rules.
- Christoph Stoller heads international Oct 31
Christoph Stoller appointed President and BU Head for International Markets, succeeding Dr. Amrut Naik who resigned effective November 7, 2026.
- Investor conference participation Nov 5
Zydus Lifesciences scheduled to participate in investor conferences in Mumbai on November 17 and November 18, 2026.
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,369 | 4,505 | 5,534 | 6,208 | 5,237 | 5,269 | 6,528 | 6,574 | 6,123 | 6,864 | 7,587 | 8,017 | 7,910 |
| Expenses | 3,223 | 3,403 | 3,903 | 4,124 | 3,776 | 3,882 | 4,402 | 4,485 | 4,107 | 5,048 | 5,033 | 6,088 | 6,015 |
| Operating Profit | 1,146 | 1,102 | 1,630 | 2,084 | 1,461 | 1,388 | 2,126 | 2,088 | 2,016 | 1,816 | 2,554 | 1,929 | 1,894 |
| OPM % | 26% | 24% | 29% | 34% | 28% | 26% | 33% | 32% | 33% | 26% | 34% | 24% | 24% |
| Other Income | 54 | 37.7 | 156 | 63 | 68 | 57 | 80.6 | 155 | 109 | 26 | 134 | 126 | 159 |
| Interest | 9 | 20 | 35 | 32 | 25 | 32 | 77 | 85 | 101 | 130 | 123 | 156 | 187 |
| Depreciation | 184 | 195 | 205 | 215 | 234 | 229 | 238 | 238 | 302 | 360 | 508 | 530 | 605 |
| Exceptional Items | — | — | — | — | — | — | −220 | — | −34.2 | — | −398 | — | — |
| PBT | 1,007 | 926 | 1,547 | 1,900 | 1,271 | 1,184 | 1,672 | 1,921 | 1,687 | 1,353 | 1,660 | 1,369 | 1,262 |
| Tax % | 22% | 23% | 21% | 23% | 29% | 15% | 25% | 23% | 27% | 29% | 19% | 26% | 26% |
| Net Profit | 803 | 790 | 1,246 | 1,482 | 920 | 1,026 | 1,244 | 1,521 | 1,239 | 1,023 | 1,341 | 1,011 | 928 |
| EPS (₹) | 7.91 | 7.80 | 11.75 | 14.11 | 9.06 | 10.17 | 11.64 | 14.58 | 12.51 | 10.36 | 12.65 | 9.63 | 9.28 |
| YoY Sales growth | 6 | 6 | 10 | 21 | 20 | 17 | 18 | 6 | 17 | 30 | 16 | 22 | 29 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 8,651 | 9,427 | 9,376 | 11,905 | 13,166 | 14,253 | 14,404 | 15,110 | 17,237 | 19,547 | 23,242 | 27,148 | 30,378 |
| Expenses | 6,896 | 7,095 | 7,474 | 9,074 | 10,174 | 11,455 | 11,013 | 11,768 | 13,378 | 14,163 | 16,183 | 18,673 | 22,183 |
| Operating Profit | 1,756 | 2,332 | 1,902 | 2,831 | 2,991 | 2,798 | 3,391 | 3,342 | 3,860 | 5,384 | 7,058 | 8,475 | 8,195 |
| OPM % | 20% | 25% | 20% | 24% | 23% | 20% | 24% | 22% | 22% | 28% | 30% | 31% | 27% |
| Other Income | 45 | 112 | 127 | 111 | 183 | −264 | −231 | 2,581 | −422 | 293 | 270 | 510 | 48 |
| Interest | 68 | 53 | 45 | 91 | 194 | 342 | 159 | 127 | 130 | 81 | 166 | 439 | 596 |
| Depreciation | 287 | 292 | 373 | 539 | 599 | 696 | 670 | 713 | 723 | 764 | 916 | 1,408 | 2,002 |
| Exceptional Items | — | — | — | — | — | — | — | — | — | — | −220 | −517 | — |
| PBT | 1,446 | 2,099 | 1,612 | 2,312 | 2,382 | 1,495 | 2,331 | 5,084 | 2,585 | 4,832 | 6,027 | 6,621 | 5,644 |
| Tax % | 18% | 8% | 8% | 24% | 22% | 21% | 8% | 10% | 23% | 20% | 23% | 24% | — |
| Net Profit | 1,188 | 1,964 | 1,517 | 1,810 | 1,899 | 1,204 | 2,185 | 4,618 | 2,092 | 3,973 | 4,673 | 5,124 | 4,302 |
| EPS (₹) | 11.24 | 18.89 | 14.53 | 17.35 | 18.06 | 11.49 | 20.84 | 43.83 | 19.37 | 38.36 | 44.97 | 50.09 | 41.92 |
| Div. Payout % | 21% | 17% | 22% | 20% | 19% | 30% | 17% | 6% | 31% | 8% | 24% | 2% | — |
| Sales growth | 20 | 9 | −1 | 27 | 11 | 8 | 1 | 5 | 14 | 13 | 19 | 17 | 24 |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 101 | 101 | 101 | 101 | 100 |
| Reserves | 4,149 | 5,597 | 6,858 | 8,642 | 10,284 | 10,273 | 12,890 | 16,897 | 17,415 | 19,729 | 23,852 | 27,011 | 27,718 |
| Borrowings | 2,651 | 2,442 | 5,207 | 5,407 | 7,899 | 7,986 | 4,608 | 4,221 | 1,195 | 804 | 3,213 | 12,496 | 13,966 |
| Other Liabilities | 2,144 | 2,208 | 2,937 | 3,632 | 4,945 | 5,115 | 6,165 | 6,421 | 6,851 | 8,201 | 9,523 | 11,065 | 13,823 |
| Total Liabilities | 9,047 | 10,350 | 15,104 | 17,783 | 23,231 | 23,477 | 23,765 | 27,642 | 25,562 | 28,834 | 36,689 | 50,673 | 55,607 |
| Fixed Assets | 3,352 | 3,748 | 5,755 | 6,483 | 12,164 | 12,230 | 12,133 | 12,188 | 11,521 | 12,368 | 13,134 | 24,106 | 27,698 |
| CWIP | 798 | 951 | 1,543 | 1,527 | 837 | 742 | 783 | 726 | 1,201 | 2,423 | 2,692 | 3,698 | 1,636 |
| Investments | 154 | 416 | 435 | 746 | 674 | 765 | 830 | 3,288 | 1,547 | 1,220 | 6,412 | 7,540 | 8,348 |
| Other Assets | 4,743 | 5,235 | 7,371 | 9,028 | 9,556 | 9,740 | 10,019 | 11,439 | 11,294 | 12,822 | 14,451 | 15,328 | 17,925 |
| Total Assets | 9,047 | 10,350 | 15,104 | 17,783 | 23,231 | 23,477 | 23,765 | 27,642 | 25,562 | 28,834 | 36,689 | 50,673 | 55,607 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 994 | 1,894 | 1,312 | 919 | 1,282 | 2,932 | 3,294 | 2,104 | 2,689 | 3,196 | 6,781 | 2,117 |
| Investing | −465 | −860 | −2,872 | −974 | −3,977 | −1,004 | −837 | −1,018 | 1,542 | −1,492 | −8,363 | −7,895 |
| Financing | −351 | −935 | 2,316 | 52 | 1,885 | −1,528 | −2,548 | −868 | −4,400 | −1,779 | 1,995 | 5,807 |
| Net Cash Flow | 178 | 99 | 756 | −3 | −811 | 399 | −90 | 219 | −170 | −75 | 414 | 28 |
| Free Cash Flow | 498 | 936 | −1,623 | −116 | 236 | 2,043 | 2,447 | 1,050 | 1,697 | 2,313 | 5,139 | −530 |
| CFO/EBITDA | 79 | 109 | 81 | 54 | 65 | 116 | 107 | 83 | 85 | 83 | 122 | 44 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 67 | 68 | 89 | 98 | 110 | 94 | 79 | 81 | 94 | 97 | 64 | 73 |
| Inventory Days | 175 | 158 | 193 | 211 | 208 | 207 | 246 | 245 | 197 | 202 | 227 | 282 |
| Days Payable | 125 | 154 | 165 | 167 | 149 | 152 | 168 | 141 | 123 | 125 | 131 | 142 |
| Cash Conversion Cycle | 118 | 71 | 116 | 142 | 169 | 149 | 158 | 185 | 168 | 175 | 160 | 212 |
| Working Capital Days | 6 | −1 | −34 | 17 | 10 | −19 | −6 | 20 | 70 | 88 | 3 | −40 |
| ROCE % | 23% | 28% | 16% | 18% | 15% | 11% | 14% | 13% | 15% | 22% | 24% | 21% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Zydus Life Science insights
72 extracted metrics across FY06–FY27.
Documents
- Q2 FY27 concall · Nov 2026Transcript PPT Recording
- Q1 FY27 concall · Aug 2026Transcript PPT Recording
- Q4 FY26 concall · May 2026Transcript PPT Recording
- Q3 FY26 concall · Feb 2026Transcript PPT Recording
- Q2 FY26 concall · Nov 2025PPT
- 22 Oct 2026
- 9 Sep 2026
- 9 Sep 2025
- 18 Mar 2025
- 27 Dec 2024
- General announcements 14 Nov 2026
- General announcements 6 Nov 2026
Frequently Asked Questions about Zydus Life Science
What does Zydus Lifesciences Ltd do?
Where is Zydus Lifesciences Ltd (ZYDUSLIFE) listed?
Which sector does Zydus Lifesciences Ltd belong to?
What is the market capitalisation of Zydus Lifesciences Ltd?
What is the PE ratio of Zydus Lifesciences Ltd?
What is the 52-week high and low of Zydus Lifesciences Ltd?
Does Zydus Lifesciences Ltd pay dividends?
What is the Return on Equity (ROE) of Zydus Lifesciences Ltd?
Company Information
In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ZYDUSLIFE.md for Zydus Lifesciences Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.